Literature DB >> 29480505

Salvage therapy outcomes for atypical meningioma.

William C Chen1, Jared Hara1, Stephen T Magill2, Ashley Wu1, Manish K Aghi2, Philip V Theodosopoulos2, Arie Perry2,3, Michael W McDermott2, Penny K Sneed1, David R Raleigh1, Steve E Braunstein4,5.   

Abstract

Atypical menginomas demonstrate increased clinical aggressiveness characterized by recurrence and diminished survival. The optimal management of atypical meningioma in the recurrent setting is especially not well defined. To characterize outcomes following salvage treatment of recurrent atypical meningioma and to identify risk factors for further recurrence. Retrospective chart review was performed on 65 patients who underwent salvage treatment of atypical meningioma at a single institution. Data were analyzed using the Kaplan-Meier method and Cox proportional hazards modeling. Sixty-five patients with recurrent atypical meningioma and median imaging follow-up of 4.0 years (range 1.9-6.6 years) underwent 62 surgeries and 114 radiation treatments (RT) for salvage therapy. Salvage modality was surgery (21%), surgery/RT (25%), or RT alone (54%), associated with 2 year local freedom from recurrence (LFFR) of 36, 59, and 73%, respectively (P = 0.01). Twenty percent of patients experienced CTCAE grade ≥ 3 toxicity with salvage therapy. Thirty-nine percent of patients experienced ≥ 3 recurrences. The median disease-free survival intervals after first and second salvage treatments were 2.9 and 1.3 years, respectively. On univariate Cox analysis, prior subtotal resection, prior RT, tumor diameter > 2.5 cm, and multifocal local recurrence were associated with recurrence after salvage therapy. On multivariate logistic regression, only multifocal local recurrence was associated with further recurrence. Recurrent atypical meningioma is clinically and pathologically more aggressive than primary atypical meningioma, and the likelihood of durable local control with salvage therapy is lower. Future efforts should identify patients at risk of recurrence, and aggressive upfront treatment should be employed.

Entities:  

Keywords:  Atypical meningioma; Meningioma; Radiation; Radiotherapy; Salvage; Stereotactic radiosurgery

Mesh:

Year:  2018        PMID: 29480505     DOI: 10.1007/s11060-018-2813-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  30 in total

1.  DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.

Authors:  Felix Sahm; Daniel Schrimpf; Damian Stichel; David T W Jones; Thomas Hielscher; Sebastian Schefzyk; Konstantin Okonechnikov; Christian Koelsche; David E Reuss; David Capper; Dominik Sturm; Hans-Georg Wirsching; Anna Sophie Berghoff; Peter Baumgarten; Annekathrin Kratz; Kristin Huang; Annika K Wefers; Volker Hovestadt; Martin Sill; Hayley P Ellis; Kathreena M Kurian; Ali Fuat Okuducu; Christine Jungk; Katharina Drueschler; Matthias Schick; Melanie Bewerunge-Hudler; Christian Mawrin; Marcel Seiz-Rosenhagen; Ralf Ketter; Matthias Simon; Manfred Westphal; Katrin Lamszus; Albert Becker; Arend Koch; Jens Schittenhelm; Elisabeth J Rushing; V Peter Collins; Stefanie Brehmer; Lukas Chavez; Michael Platten; Daniel Hänggi; Andreas Unterberg; Werner Paulus; Wolfgang Wick; Stefan M Pfister; Michel Mittelbronn; Matthias Preusser; Christel Herold-Mende; Michael Weller; Andreas von Deimling
Journal:  Lancet Oncol       Date:  2017-03-15       Impact factor: 41.316

2.  Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups.

Authors:  F G Davis; V Kupelian; S Freels; B McCarthy; T Surawicz
Journal:  Neuro Oncol       Date:  2001-07       Impact factor: 12.300

Review 3.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

Review 4.  Medical therapies for meningiomas.

Authors:  Patrick Y Wen; Eudocia Quant; Jan Drappatz; Rameen Beroukhim; Andrew D Norden
Journal:  J Neurooncol       Date:  2010-09-04       Impact factor: 4.130

5.  Atypical meningiomas: is postoperative radiotherapy indicated?

Authors:  Kangmin D Lee; John J DePowell; Ellen L Air; Alok K Dwivedi; Ady Kendler; Christopher M McPherson
Journal:  Neurosurg Focus       Date:  2013-12       Impact factor: 4.047

6.  Atypical and malignant meningioma: outcome and prognostic factors in 68 irradiated patients.

Authors:  Beatrice Detti; Silvia Scoccianti; Vanessa Di Cataldo; Eleonora Monteleone; Samantha Cipressi; Lorenzo Bordi; Gianni Pellicanò; Davide Gadda; Calogero Saieva; Daniela Greto; Guido Pecchioli; Annamaria Buccoliero; Marco Ceroti; Franco Ammannati; Giampaolo Biti
Journal:  J Neurooncol       Date:  2013-09-18       Impact factor: 4.130

7.  Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation.

Authors:  Manish K Aghi; Bob S Carter; Garth R Cosgrove; Robert G Ojemann; Sepideh Amin-Hanjani; Robert L Martuza; William T Curry; Fred G Barker
Journal:  Neurosurgery       Date:  2009-01       Impact factor: 4.654

8.  The role of radiotherapy following gross-total resection of atypical meningiomas.

Authors:  Ricardo J Komotar; J Bryan Iorgulescu; Daniel M S Raper; Eric C Holland; Kathryn Beal; Mark H Bilsky; Cameron W Brennan; Viviane Tabar; Jonathan H Sherman; Yoshiya Yamada; Philip H Gutin
Journal:  J Neurosurg       Date:  2012-08-24       Impact factor: 5.115

9.  Surgical Resection and Interstitial Iodine-125 Brachytherapy for High-Grade Meningiomas: A 25-Year Series.

Authors:  Stephen T Magill; Darryl Lau; David R Raleigh; Penny K Sneed; Shannon E Fogh; Michael W McDermott
Journal:  Neurosurgery       Date:  2017-03-01       Impact factor: 4.654

10.  Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539.

Authors:  Leland Rogers; Peixin Zhang; Michael A Vogelbaum; Arie Perry; Lynn S Ashby; Jignesh M Modi; Anthony M Alleman; James Galvin; David Brachman; Joseph M Jenrette; John De Groot; Joseph A Bovi; Maria Werner-Wasik; Jonathan P S Knisely; Minesh P Mehta
Journal:  J Neurosurg       Date:  2017-10-06       Impact factor: 5.115

View more
  6 in total

1.  Outcomes of salvage radiation for recurrent world health organization grade II meningiomas: a retrospective cohort study.

Authors:  Arbaz A Momin; Jianning Shao; Pranay Soni; João Paulo Almeida; John H Suh; Erin S Murphy; Samuel T Chao; Lilyana Angelov; Alireza M Mohammadi; Gene H Barnett; Pablo F Recinos; Varun R Kshettry
Journal:  J Neurooncol       Date:  2021-02-15       Impact factor: 4.130

2.  Advances in multidisciplinary therapy for meningiomas.

Authors:  Priscilla K Brastianos; Evanthia Galanis; Nicholas Butowski; Jason W Chan; Ian F Dunn; Roland Goldbrunner; Christel Herold-Mende; Franziska M Ippen; Christian Mawrin; Michael W McDermott; Andrew Sloan; James Snyder; Ghazaleh Tabatabai; Marcos Tatagiba; Joerg C Tonn; Patrick Y Wen; Kenneth Aldape; Farshad Nassiri; Gelareh Zadeh; Michael D Jenkinson; David R Raleigh
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

Review 3.  Adjuvant radiotherapy versus observation following gross total resection for atypical meningioma: a systematic review and meta-analysis.

Authors:  Se-Woong Chun; Kyung Min Kim; Min-Sung Kim; Ho Kang; Yun-Sik Dho; Youngbeom Seo; Jin Wook Kim; Yong Hwy Kim; Chul-Kee Park
Journal:  Radiat Oncol       Date:  2021-02-17       Impact factor: 3.481

4.  Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review.

Authors:  Katherine Belanger; Timothy H Ung; Denise Damek; Kevin O Lillehei; D Ryan Ormond
Journal:  BMC Cancer       Date:  2022-04-07       Impact factor: 4.430

5.  A Prognostic Gene-Expression Signature and Risk Score for Meningioma Recurrence After Resection.

Authors:  William C Chen; Harish N Vasudevan; Abrar Choudhury; Melike Pekmezci; Calixto-Hope G Lucas; Joanna Phillips; Stephen T Magill; Matthew S Susko; Steve E Braunstein; Nancy Ann Oberheim Bush; Lauren Boreta; Jean L Nakamura; Javier E Villanueva-Meyer; Penny K Sneed; Arie Perry; Michael W McDermott; David A Solomon; Philip V Theodosopoulos; David R Raleigh
Journal:  Neurosurgery       Date:  2020-12-15       Impact factor: 5.315

6.  Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma.

Authors:  Stephen T Magill; Harish N Vasudevan; Kyounghee Seo; Javier E Villanueva-Meyer; Abrar Choudhury; S John Liu; Melike Pekmezci; Sarah Findakly; Stephanie Hilz; Sydney Lastella; Benjamin Demaree; Steve E Braunstein; Nancy Ann Oberheim Bush; Manish K Aghi; Philip V Theodosopoulos; Penny K Sneed; Adam R Abate; Mitchel S Berger; Michael W McDermott; Daniel A Lim; Erik M Ullian; Joseph F Costello; David R Raleigh
Journal:  Nat Commun       Date:  2020-09-23       Impact factor: 17.694

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.